IL13 and Alzheimer disease: A clinical trial assessed the safety of dupilumab, an anti-IL-4Rα antibody that inhibits the release of Il-4 and Il-13, the key cytokines released by Th2 in AD, in AA after several cases of hair growth were reported in the literature following the administration of dupilumab to patients with AA and AD [78].